as of 11-20-2026 2:43pm EST
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | LOS GATOS |
| Market Cap: | 4.8M | IPO Year: | 2021 |
| Target Price: | $6.00 | AVG Volume (30 days): | 95.4K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -22.48 | EPS Growth: | 84.90 |
| 52 Week Low/High: | $0.96 - $40.95 | Next Earning Date: | 11-12-2026 |
| Revenue: | $3,944,000 | Revenue Growth: | 20.35% |
| Revenue Growth (this year): | 44.38% | Revenue Growth (next year): | 39.49% |
| P/E Ratio: | -0.04 | Index: | N/A |
| Free Cash Flow: | -11018000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
10% Owner
Avg Cost/Share
$3.95
Shares
67,925
Total Value
$246,296.70
Owned After
15,839
10% Owner
Avg Cost/Share
$5.56
Shares
65,582
Total Value
$364,635.92
Owned After
15,839
SEC Form 4
10% Owner
Avg Cost/Share
$3.40
Shares
39,508
Total Value
$134,327.20
Owned After
15,839
SEC Form 4
10% Owner
Avg Cost/Share
$3.44
Shares
60,343
Total Value
$174,008.91
Owned After
15,839
10% Owner
Avg Cost/Share
$3.34
Shares
707
Total Value
$2,361.38
Owned After
15,839
SEC Form 4
10% Owner
Avg Cost/Share
$3.70
Shares
1,506
Total Value
$5,572.20
Owned After
15,839
SEC Form 4
10% Owner
Avg Cost/Share
$3.98
Shares
1,658
Total Value
$6,598.84
Owned After
15,839
SEC Form 4
10% Owner
Avg Cost/Share
$4.53
Shares
450
Total Value
$2,038.50
Owned After
15,839
SEC Form 4
10% Owner
Avg Cost/Share
$4.57
Shares
1,790
Total Value
$8,180.30
Owned After
15,839
SEC Form 4
10% Owner
Avg Cost/Share
$4.66
Shares
1,276
Total Value
$5,946.16
Owned After
15,839
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 10, 2026 | Buy | $3.95 | 67,925 | $246,296.70 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 10, 2026 | Sell | $5.56 | 65,582 | $364,635.92 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 9, 2026 | Buy | $3.40 | 39,508 | $134,327.20 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 9, 2026 | Sell | $3.44 | 60,343 | $174,008.91 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 8, 2026 | Buy | $3.34 | 707 | $2,361.38 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 4, 2026 | Sell | $3.70 | 1,506 | $5,572.20 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 3, 2026 | Buy | $3.98 | 1,658 | $6,598.84 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 2, 2026 | Sell | $4.53 | 450 | $2,038.50 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Sep 1, 2026 | Buy | $4.57 | 1,790 | $8,180.30 | 15,839 | |
| HRT FINANCIAL LP | TNON | 10% Owner | Aug 31, 2026 | Sell | $4.66 | 1,276 | $5,946.16 | 15,839 |
SEC 8-K filings with transcript text
Nov 12, 2026 · 100% conf.
1D
+4.86%
$1.88
Act: -21.23%
5D
+14.79%
$2.05
20D
+6.43%
$1.91
2 ea031209601ex99-1.htm
Exhibit 99.1
Tenon® Medical Reports Third Quarter 2026 Financial Results
~ Third Quarter 2026 Revenue of $1.4 Million, a 22% Increase Compared to Prior Year ~
~ Third Quarter Gross Profit of $1.0 Million, a 23% Increase Compared to Prior Year; Gross Margin of 66.3% ~
~ Raised Approximately $15.6 Million in Gross Proceeds, Repaid Convertible Notes in Full and Ended the Quarter with $8.3 Million in Cash and Cash Equivalents ~
~ Commenced Full Commercial Launch of 3D-Printed Lateral Screw for the SImmetry®+ SI Joint Fusion System ~
~ Added Eight New U.S. Patents in 2026, Bringing Portfolio to 38 Issued U.S. Patents ~
Los Gatos, CA – November 12, 2026 – Tenon Medical, Inc. (NASDAQ: TNON) (“Tenon Medical” or the “Company”), a company redefining care for patients with sacro-pelvic disorders, today reported financial results for the third quarter ended September 30, 2026.
Financial Results and Business Updates
●Third Quarter 2026 Results:
○Third quarter revenue of $1.4 million, an increase of 22% compared to $1.2 million in the third quarter of 2025.
○Third quarter gross profit of $1.0 million, an increase of 23% compared to $0.8 million in the third quarter of 2025.
○Gross margin of 66.3%, a 0.4 percentage point increase from 65.9% in the third quarter of 2025.
○Cash and cash equivalents of $8.3 million as of September 30, 2026, compared to $3.8 million as of December 31, 2025.
○Operating loss of $3.1 million in the third quarter, an improvement of $0.3 million compared to $3.4 million in the third quarter of 2025.
○Net loss of $6.6 million, or $5.39 per share, in the third quarter of 2026, compared to a net loss of $3.3 million, or $14.17 per share, in the third quarter of 2025.
●Commercially launched the 3D-printed lateral screw for the SImmetry®+ SI Joint Fusion System, the first component of a next-generation lateral system, following an alpha launch that generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026.
●Raised approximately $15.6 million in aggregate gross proceeds and regained compliance with Nasdaq’s minimum stockholders’ equity requirement. The Company also regained compliance with Nasdaq’s minimum bid price requirement following its 1-for-35 reverse stock split, effective August 10, 2026.
●Repaid in full approximately $5.12 million of remaining principal balance of senior convertible notes ahead of their September 11, 2026 maturity.
Subsequent Updates
●The Company hired Thomas Batton Jr. as Chief Revenue Officer, effective October 1, 2026, to lead the commercial organization. Mr. Batton has over 15 years of medical device sales and commercial leadership experience across spine, neuromodulation and pain management, including extensive experience within SI joint fixation. The Company plans to continue to add to its commercial organization through hiring direct sales representatives and onboarding distributor partners.
●On October 15, 2026, the Company announced that the U.S. Patent and Trademark Office had issued eight new patents to the Company so far in 2026, bringing its portfolio to 38 issued U.S. patents and nine international patents, with 31 U.S. and foreign patent applications pending. The patents include both system and method claims covering the Catamaran® SI Joint Fusion System and are expected to strengthen the Company’s intellectual property position in the sacro-pelvic fusion market.
●On October 28, 2026, the Company announced the completion of the initial alpha cases of its new Quickstep™ Decorticator for the next-generation SImmetry®+ SI Joint Fusion System. Quickstep is designed to streamline joint decortication and simplify the SImmetry+ surgical workflow, and the Company is targeting full market release in the first quarter of 2027.
“Third quarter revenue of $1.4 million grew 22% compared to the prior year and 12% sequentially from the second quarter, and we delivered that growth while reducing operating expenses compared to both the third quarter of 2025 and the second quarter of this year,” said Steven M. Foster, President and CEO of Tenon Medical, Inc. “Just as importantly, we significantly strengthened our balance sheet during the quarter. We raised approximately $15.6 million in aggregate gross proceeds, repaid our convertible notes in full, regained compliance with Nasdaq’s stockholders’ equity and minimum bid price requirements, and ended the quarter with $8.3 million in cash.”
“With our convertible notes now behind us, our attention is fully on growth. The full commercial launch of our 3D-printed SImmetry®+ lateral screw, the first component of our next-generation lateral system, and the completion of initial alpha cases with our Quickstep™ Decorticator, which we are targeting for full market release in the first quarter of 2027, expand the tools we can offer our physician partners. Our eig
Aug 13, 2026 · 100% conf.
1D
-5.50%
$5.63
Act: -13.42%
5D
-9.99%
$5.36
20D
-18.82%
$4.84
Transcript text not available. View on SEC.gov →
May 12, 2026
See how TNON stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "TNON Tenon Medical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.